var data={"title":"Diagnosis and management of bioprosthetic valve thrombosis and obstruction","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Diagnosis and management of bioprosthetic valve thrombosis and obstruction</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/contributors\" class=\"contributor contributor_credentials\">Sorin Pislaru, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/contributors\" class=\"contributor contributor_credentials\">Heidi M Connolly, MD, FASE</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/contributors\" class=\"contributor contributor_credentials\">William H Gaasch, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/contributors\" class=\"contributor contributor_credentials\">Stephen JD Brecker, MD, FRCP, FESC, FACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/contributors\" class=\"contributor contributor_credentials\">Susan B Yeon, MD, JD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 03, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3219840367\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Replacement of a diseased heart valve with a prosthetic heart valve exchanges the native disease for prosthesis-related complications [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Complications include prosthetic valve obstruction (including prosthetic valve thrombosis [PVT] and pannus formation), embolic events, bleeding, prosthetic heart valve regurgitation (valvular and paravalvular), infective endocarditis, and prosthetic valve-related hemolysis. Thrombus forming on a bioprosthetic valve can be nonobstructive or obstructive and may or may not cause clinical thromboembolic events [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/4-7\" class=\"abstract_t\">4-7</a>]. (See <a href=\"topic.htm?path=overview-of-the-management-of-patients-with-prosthetic-heart-valves\" class=\"medical medical_review\">&quot;Overview of the management of patients with prosthetic heart valves&quot;</a>.)</p><p>A bioprosthetic valve can be implanted surgically or via a transcatheter procedure. This topic discusses the diagnosis and management of bioprosthetic valve thrombosis (BPVT) and bioprosthetic valve obstruction for surgically implanted valves. The clinical manifestations and initial evaluation of PVT and the diagnosis and management of mechanical valve thrombosis and obstruction are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-initial-evaluation-of-prosthetic-valve-thrombosis-and-obstruction\" class=\"medical medical_review\">&quot;Clinical manifestations and initial evaluation of prosthetic valve thrombosis and obstruction&quot;</a> and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;</a>.)</p><p>Management of bioprosthetic obstruction and thrombosis during pregnancy differs from the approach presented here, as discussed separately. (See <a href=\"topic.htm?path=management-of-risks-of-prosthetic-valves-during-pregnancy#H2176921576\" class=\"medical medical_review\">&quot;Management of risks of prosthetic valves during pregnancy&quot;, section on 'Risks associated with prosthetic valves'</a>.)</p><p class=\"headingAnchor\" id=\"H1083569417\"><span class=\"h1\">APPROACH TO EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our general approach to evaluating patients with suspected BPVT <span class=\"nowrap\">and/or</span> obstruction is presented here (<a href=\"image.htm?imageKey=CARD%2F116059\" class=\"graphic graphic_algorithm graphicRef116059 \">algorithm 1</a>). </p><p class=\"headingAnchor\" id=\"H642780392\"><span class=\"h2\">Initial evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As discussed separately, the initial evaluation of BPVT or bioprosthetic valve obstruction includes: identification of patients suspected of having either or both of these disorders and initial imaging (generally by transthoracic echocardiography [TTE]) including determination of whether prosthetic valve obstruction (or regurgitation) is present. Prosthetic valve obstruction is defined as mean transvalvular gradient increase by &gt;50 percent [or &gt;10 mmHg increase for an aortic prosthesis] compared with baseline, after exclusion of other causes such as a high-output state. (See <a href=\"topic.htm?path=clinical-manifestations-and-initial-evaluation-of-prosthetic-valve-thrombosis-and-obstruction#H3800172701\" class=\"medical medical_review\">&quot;Clinical manifestations and initial evaluation of prosthetic valve thrombosis and obstruction&quot;, section on 'Initial evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H1561130580\"><span class=\"h2\">Further evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest the following approach to further testing after the initial evaluation. This evaluation is expedited in patients with bioprosthetic valve obstruction causing moderate to severe symptoms (New York Heart Association [NYHA] functional class III or IV) or with high-risk left-sided bioprosthetic valve thrombus (ie, a mobile thrombus &gt;0.3 cm in diameter or any thrombus with area &ge;1.0 cm<sup>2</sup>). (See <a href=\"#H3005844480\" class=\"local\">'Urgent management of bioprosthetic valve obstruction or high-risk thrombus'</a> below and <a href=\"#H3374411767\" class=\"local\">'Left-sided valve thrombosis'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Further imaging of the bioprosthetic valve by transesophageal echocardiography (TEE) <span class=\"nowrap\">and/or</span> four-dimensional volume-rendered computed tomography (4D CT). Factors to consider when choosing between TEE and 4D CT are described below. If the bioprosthetic valve is not adequately visualized by TEE or 4D CT, we suggest performing the alternate test, if feasible. (See <a href=\"#H1989277313\" class=\"local\">'Choice between TEE or 4D CT'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exclude prosthetic valve endocarditis. (See <a href=\"#H3743821520\" class=\"local\">'Exclude prosthetic valve endocarditis'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A presumptive diagnosis of presence or absence of prosthetic valve thrombosis is made based upon the results of prosthetic valve imaging. (See <a href=\"#H3346496544\" class=\"local\">'How to diagnose prosthetic valve thrombosis'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition, for patients with thromboembolic event (eg stroke), comprehensive evaluation for alternative causes should be conducted. (See <a href=\"topic.htm?path=clinical-manifestations-and-initial-evaluation-of-prosthetic-valve-thrombosis-and-obstruction#H3271337419\" class=\"medical medical_review\">&quot;Clinical manifestations and initial evaluation of prosthetic valve thrombosis and obstruction&quot;, section on 'For valve thrombosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1989277313\"><span class=\"h3\">Choice between TEE or 4D CT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice between TEE and 4D CT as the initial imaging test after TTE is made based upon availability, prior test results, patient characteristics, bioprosthetic valve location and characteristics, and clinician experience. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When to start with TEE (see <a href=\"#H2775584315\" class=\"local\">'Transesophageal echocardiography'</a> below):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If TTE assessment of prosthetic valve gradients is suboptimal, TEE is preferred as it may be helpful in assessing valve gradients.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>TEE is preferred for prosthetic mitral and tricuspid valves.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>TEE is slightly preferred to 4D CT if other causes of emboli such as atrial thrombi or vegetations are suspected. (See <a href=\"#H4239874177\" class=\"local\">'Characteristics of imaging tests'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When to start with 4D CT (see <a href=\"#H3403465757\" class=\"local\">'4D Computed tomography'</a> below):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>4D CT is preferred for the patient with contraindication to TEE.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>4D CT may be preferred for prosthetic aortic and pulmonic valves.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>4D CT is preferred for a patient known to have suboptimal TEE prosthetic valve images.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>4D CT may be preferred for transcatheter heart valves, particularly when prior TEE imaging demonstrates valve leaflets are difficult to visualize.</p><p/><p class=\"headingAnchor\" id=\"H4239874177\"><span class=\"h4\">Characteristics of imaging tests</span></p><p class=\"headingAnchor\" id=\"H2775584315\"><span class=\"h5\">Transesophageal echocardiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TEE enables assessment of prosthetic valve leaflet appearance, motion and function (obstruction and regurgitation), features of thrombus, and alternate causes of emboli. Three-dimensional TEE is suggested when available, as it may detect prosthetic thrombi that are missed or only partially visualized by two-dimensional TEE [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/8\" class=\"abstract_t\">8</a>]. </p><p class=\"headingAnchor\" id=\"H3403465757\"><span class=\"h5\">4D Computed tomography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Four-dimensional volume-rendered CT (4D CT) enables assessment of prosthetic valve leaflet appearance and motion and features of thrombus [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/9\" class=\"abstract_t\">9</a>]. </p><p>Cardiac CT is also helpful for identifying alternative diagnoses (similar to TEE), as it can identify vegetations with accuracy approaching that of TEE [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/10\" class=\"abstract_t\">10</a>], and cardiac CT with a delayed imaging acquisition protocol can identify atrial thrombi with accuracy nearing that of TEE [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/11,12\" class=\"abstract_t\">11,12</a>]. (See <a href=\"topic.htm?path=echocardiographic-evaluation-of-prosthetic-heart-valves\" class=\"medical medical_review\">&quot;Echocardiographic evaluation of prosthetic heart valves&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H3743821520\"><span class=\"h3\">Exclude prosthetic valve endocarditis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients presenting with abnormal prosthetic valve appearance or mobility, it is important to exclude the presence of prosthetic valve endocarditis (PVE). PVE generally presents with signs and symptoms of invasive infection but may occasionally have an occult presentation; clinical manifestations and diagnosis are discussed separately. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis&quot;</a>.)</p><p>If imaging and clinical findings support a diagnosis of PVE (eg, presence of vegetations and positive blood cultures), then appropriate management including antimicrobial therapy is indicated. </p><p>If a diagnosis of PVE is uncertain, follow-up testing (eg, repeat TEE in one week) is recommended to determine whether or not PVE is present. </p><p class=\"headingAnchor\" id=\"H3346496544\"><span class=\"h2\">How to diagnose prosthetic valve thrombosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>BPVT is presumptively diagnosed when <strong>both</strong> of the following features are present:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diffuse or focal increased cusp thickness</strong> (&gt;2 mm) with a soft echodensity on TEE or a hypoattenuated appearance on 4D CT.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The mass usually respects the cusp edges, unlike pannus. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Bioprosthetic thrombus is generally located on the downstream side of the valve [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/13\" class=\"abstract_t\">13</a>], although bioprosthetic mitral valve thrombosis has also been visualized on the upstream side of the valve [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/14\" class=\"abstract_t\">14</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Presence of more than mild cusp calcification is usually associated with a degenerated bioprosthetic valve rather than thrombus. However, the presence of valve calcification does not rule out a thrombotic component, particularly if other imaging features clearly suggest thrombus.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Impaired cusp mobility.</strong> However, bioprosthetic valve cusp immobility alone is not diagnostic of BPVT [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/15\" class=\"abstract_t\">15</a>]. </p><p/><p>The diagnosis of BPVT may be confirmed by resolution of prosthetic valve <span class=\"nowrap\">thickening/mass</span> with anticoagulation or pathologic inspection after prosthesis removal. (See <a href=\"#H1836028158\" class=\"local\">'Optimizing antithrombotic therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H89053030\"><span class=\"h2\">Evidence on imaging bioprosthetic valve obstruction and thrombosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited data are available on distinguishing bioprosthetic valve thrombus and pannus. Presence of a soft echodensity downstream of the valve, resulting in thickened cusps with reduced mobility, is the typical appearance of thrombus. By contrast, pannus usually appears to overlay the valve and results in echodense appearance of the cusp with reduced mobility, and sometimes areas of calcification.</p><p>The following results were obtained from a retrospective study of 32 patients with BPVT (aortic, mitral, tricuspid, or pulmonic) [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/16\" class=\"abstract_t\">16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnostic value of three echocardiographic criteria for the diagnosis of obstructive BPVT was assessed:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A greater than 50 percent increase in mean prosthetic valve gradient from baseline within five years</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Increased cusp thickness</p><p/><p class=\"bulletIndent2\"><strong>AND</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Impaired cusp mobility </p><p/><p>Concomitant presence of these three criteria predicted BPVT with 72 percent sensitivity and 90 percent specificity. Additional risk factors for BPVT were paroxysmal atrial fibrillation and presence of a subtherapeutic international normalized ratio (INR). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fifteen patients were initially treated with vitamin K antagonist (VKA) plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, and 17 were initially treated with surgery (15) or fibrinolysis (2).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal prosthetic valve function with resolution of thrombus was achieved in 13 of 15 patients treated with VKA and 17 of 17 patients treated with surgery or fibrinolysis. Gastrointestinal bleeding requiring transfusion occurred in one patient treated with VKA and in one treated with surgery. </p><p/><p>The diagnostic value of these three criteria was confirmed in a prospective study of 52 patients with suspected BPVT followed for a mean of 86 weeks. Presence of all three criteria predicted a positive response (&ge;50 percent reduction in mean valve gradient) to VKA therapy with a sensitivity of 88 percent, specificity of 93 percent, positive predictive value of 91 percent, and negative predictive value of 85 percent [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H953686112\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H5869880\"><span class=\"h2\">General considerations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of prosthetic valve thrombosis (PVT) <span class=\"nowrap\">and/or</span> thromboembolism involves management of the acute risk and selection of therapy for long-term management. The evaluation of bioprosthetic valve obstruction is closely linked to management since some therapies (such as valve surgery or a trial of anticoagulant therapy) may both identify the cause of prosthetic valve obstruction and treat it (<a href=\"image.htm?imageKey=CARD%2F116059\" class=\"graphic graphic_algorithm graphicRef116059 \">algorithm 1</a>). </p><p>Factors influencing the choice of therapy include presence of symptomatic obstruction, cause of obstruction, valve location (left- or right-sided), thrombus size, and thrombus mobility [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/2,3,18-20\" class=\"abstract_t\">2,3,18-20</a>]. While thrombus size is commonly used as a factor guiding management, it should be noted that it is difficult to quantify thrombus size due to prosthesis imaging artifact and other technical limitations. </p><p>The following approach is based largely on expert opinion. Randomized controlled data for the therapy of PVT are not available, and each therapeutic option has important limitations, including periprocedural risk of mortality and morbidity with valve surgery or transcatheter intervention, risk of bleeding and systemic embolization with fibrinolytic therapy, and risk of failure to improve with intravenous (IV) heparin therapy. </p><p>The approach discussed here is in broad agreement with the 2017 update of the 2014 American Heart <span class=\"nowrap\">Association/American</span> College of Cardiology <span class=\"nowrap\">(AHA/ACC)</span> valvular heart disease guidelines [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/21\" class=\"abstract_t\">21</a>]. A somewhat similar approach was recommended in the 2017 European Society of Cardiology guidelines [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/3\" class=\"abstract_t\">3</a>]. </p><p class=\"headingAnchor\" id=\"H3005844480\"><span class=\"h2\">Urgent management of bioprosthetic valve obstruction or high-risk thrombus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urgent management of moderately to severely symptomatic (New York Heart Association [NYHA] functional class III or IV) bioprosthetic valve obstruction or high-risk left-sided valve thrombus (ie, a mobile thrombus &gt;0.3 cm in diameter or any thrombus with area &ge;1.0 cm<sup>2</sup>) includes temporizing supportive medical care, expedited evaluation, and urgent Heart Valve Team assessment to guide further care. </p><p>Limited evidence is available on urgent management of BPVT and obstruction. (See <a href=\"#H2161656995\" class=\"local\">'Components of therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H3992733555\"><span class=\"h3\">Temporizing medical care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive medical care for moderately to severely symptomatic bioprosthetic valve obstruction includes respiratory support as needed, cautious treatment of hypertension, and treatment of heart failure (HF) with cautious use of diuretics to treat volume overload. Medical therapies such as diuretics and antihypertensive agents pose the risk of destabilizing the patient with symptomatic prosthetic valve obstruction. (See <a href=\"#H141470734\" class=\"local\">'Medical therapy for heart failure'</a> below.)</p><p>In patients with BPVT requiring urgent therapy, vitamin K antagonist (VKA) is held, and IV <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">unfractionated heparin</a> (UFH) is added to low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> as soon as this is recognized.</p><p class=\"headingAnchor\" id=\"H1476339903\"><span class=\"h3\">Urgent Heart Valve Team assessment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with bioprosthetic valve obstruction causing moderate to severe symptoms (NYHA functional class III or IV) or with high-risk left-sided bioprosthetic valve thrombus (ie, a mobile thrombus &gt;0.3 cm in diameter or any thrombus with area &ge;1.0 cm<sup>2</sup>) require urgent evaluation by a Heart Valve Team (including a cardiac surgeon) to guide the expedited diagnostic evaluation and the choice among valve surgery, transcatheter intervention, fibrinolytic therapy (if thrombus is suspected), or palliative care, as described below. (See <a href=\"#H1064840080\" class=\"local\">'Referral to Heart Valve Team'</a> below.)</p><p class=\"headingAnchor\" id=\"H3873861971\"><span class=\"h3\">Recommendations for urgent therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presumptive cause of bioprosthetic valve obstruction guides the therapeutic choices. The urgency of treatment depends upon the acuity and severity of the patient&rsquo;s symptoms. (See <a href=\"#H1064840080\" class=\"local\">'Referral to Heart Valve Team'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For obstructive thrombosis: </strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Left-sided:</strong> Patients with left-sided obstructive BPVT causing NYHA class III to IV symptoms require urgent intervention. For most of these patients, we suggest surgery rather than fibrinolysis. This recommendation is based upon indirect evidence from observational studies in patients with mechanical PVT showing low efficacy and high rates of complications in patients with moderate to severe symptoms treated with fibrinolytic therapy. (See <a href=\"#H2362151669\" class=\"local\">'Fibrinolysis'</a> below and <a href=\"#H835657915\" class=\"local\">'Surgery'</a> below and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H2287838960\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'Fibrinolytic therapy'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Right-sided:</strong> Patients with right-sided obstructive BPVT causing NYHA class III to IV symptoms require urgent intervention. For most of these patients, we suggest fibrinolysis rather than surgery. This recommendation is based upon very limited observational evidence in patients with right-sided obstructive BPVT and indirect observational studies in patients with mechanical valve PVT. (See <a href=\"#H420377861\" class=\"local\">'Evidence on fibrinolytic protocols'</a> below and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1679702231\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For right-sided PVT'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For mobile or large thrombus:</strong> Patients with left-sided BPVT (obstructive or nonobstructive) with a mobile thrombus &ge;0.3 cm in diameter or a large nonmobile thrombus (&ge;1.0 cm<sup>2</sup>) require urgent intervention. For most of these patients, we suggest surgery rather than fibrinolysis. This recommendation is based upon indirect evidence from observational studies in patients with left-sided mechanical valve thrombosis. (See <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H2812891314\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For left-sided PVT'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For pannus or calcification</strong> &mdash; Patients with bioprosthetic valve obstruction due to pannus or calcification causing moderate to severe symptoms (NYHA functional class III or IV) require urgent intervention; the treatment options are surgery or transcatheter intervention. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For such patients who are judged by a Heart Valve Team to be at high or greater risk for open surgical therapy (ie, Society of Thoracic Surgeons [STS] operative risk score &gt;8 percent or a &gt;15 percent risk of mortality at 30 days), we suggest a transcatheter valve-in-valve (TViV) procedure at a center with expertise in this procedure. (See <a href=\"#H2776974637\" class=\"local\">'Transcatheter intervention'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients who are judged by a Heart Valve Team to be at low or intermediate risk with open surgical therapy (ie, STS operative risk score &le;8 percent or a &le;15 percent risk of mortality at 30 days), the options are surgical valve replacement or a TViV procedure at a center with expertise in this procedure. The available limited observational data suggest similar operative mortality, lower operative morbidity, similar long-term mortality, and higher risk of paravalvular regurgitation with TViV compared with surgical valve replacement. (See <a href=\"#H2776974637\" class=\"local\">'Transcatheter intervention'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For <span class=\"nowrap\">pannus/calcification</span> plus thrombus </strong>&mdash; For patients with clinical and imaging features consistent with prosthetic valve thrombus plus pannus with moderately to severely symptomatic obstruction, the treatment options are fibrinolysis or surgery. In this setting, surgery is generally preferred because fibrinolysis has no effect on pannus and would be unlikely to result in complete resolution of the obstruction. In this setting, fibrinolysis is an option only for hemodynamically stable patients who have clear evidence of predominant thrombus. </p><p/><p class=\"headingAnchor\" id=\"H1881821939\"><span class=\"h2\">Non-urgent management of bioprosthetic valve obstruction or thrombosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with bioprosthetic valve obstruction with no or mild symptoms (NYHA class I or II) or BPVT without high-risk features, we suggest the following approaches. </p><p class=\"headingAnchor\" id=\"H3506535411\"><span class=\"h3\">For prosthetic valve obstruction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with asymptomatic or mildly symptomatic (NYHA functional class I or II) prosthetic valve obstruction, management is aimed at treating symptoms of HF and treating the obstruction (eg, thrombus or pannus). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medical treatment of symptomatic HF with cautious use of diuretics and antihypertensive agents (eg angiotensin converting enzyme inhibitor), given risk of hemodynamic instability with attempted therapy. (See <a href=\"#H141470734\" class=\"local\">'Medical therapy for heart failure'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of obstruction depends upon the presumptive cause and the severity of symptoms.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Thrombosis: </strong>If the patient has a presumptive diagnosis of left-sided BPVT, we suggest a trial of anticoagulation and further management as discussed below. (See <a href=\"#H2967841569\" class=\"local\">'For valve thrombosis'</a> below.)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span><strong>Left-sided:</strong> For patients with obstructive left-sided BPVT, we suggest a trial of anticoagulation. We treat with one or more 30-day trials of VKA, with further management as described below. <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> 75 to 100 <span class=\"nowrap\">mg/day</span> is continued. (See <a href=\"#H2967841569\" class=\"local\">'For valve thrombosis'</a> below and <a href=\"#H1836028158\" class=\"local\">'Optimizing antithrombotic therapy'</a> below.)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span><strong>Right-sided:</strong> For patients with obstructive right-sided BPVT, we suggest fibrinolytic therapy rather than anticoagulation. This recommendation is based upon limited observational evidence in patients with right-sided BPVT and indirect evidence from observational studies in patients with right-sided mechanical PVT. (See <a href=\"#H1836028158\" class=\"local\">'Optimizing antithrombotic therapy'</a> below and <a href=\"#H420377861\" class=\"local\">'Evidence on fibrinolytic protocols'</a> below and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1679702231\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For right-sided PVT'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Pannus or calcification: </strong>If a patient with mildly symptomatic obstruction has a presumptive diagnosis of pannus or calcification, the patient is referred to a Heart Valve Team for an individualized assessment of the <span class=\"nowrap\">risk/benefit</span> of valve surgery, transcatheter intervention, or palliative care. The approach to choosing between open surgery and transcatheter intervention is the same as that described above for patients with moderately to severely symptomatic obstruction. (See <a href=\"#H1064840080\" class=\"local\">'Referral to Heart Valve Team'</a> below and <a href=\"#H2776974637\" class=\"local\">'Transcatheter intervention'</a> below and <a href=\"#H835657915\" class=\"local\">'Surgery'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Both <span class=\"nowrap\">pannus/calcification</span> and thrombosis: </strong>For patients with clinical and imaging features consistent with BPVT plus pannus or calcification with moderately to severely symptomatic obstruction, the treatment options are fibrinolysis or surgery. Surgery is generally preferred in this setting because fibrinolysis has no effect on pannus and would be unlikely to result in complete resolution of the obstruction. Fibrinolysis is an option only for hemodynamically stable patients who have clear evidence of predominant thrombus. The presence of thrombus is a relative contraindication to a valve-in-valve procedure.</p><p/><p class=\"headingAnchor\" id=\"H2967841569\"><span class=\"h3\">For valve thrombosis</span></p><p class=\"headingAnchor\" id=\"H3374411767\"><span class=\"h4\">Left-sided valve thrombosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with left-sided (ie, aortic or mitral) BPVT with no obstruction or obstruction with no or mild symptoms (NYHA class I or II) and small thrombus (nonmobile and &lt;1.0 cm<sup>2</sup> or mobile and &lt;0.3 cm in diameter) or right-sided BPVT, treatment is aimed at thrombus resolution. We suggest the following approach to management of patients with presumptive BPVT based on observational data and our clinical experience (see <a href=\"#H1836028158\" class=\"local\">'Optimizing antithrombotic therapy'</a> below):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Therapeutic anticoagulation. The standard anticoagulant used for BPVT is VKA (eg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>). We suggest one or more 30-day trials of VKA with a target international normalized ratio (INR) of 2.5 plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> 75 to 100 <span class=\"nowrap\">mg/day</span>. </p><p/><p class=\"bulletIndent1\">Some experts use direct oral anticoagulants (oral direct thrombin inhibitors and factor Xa inhibitors) in patients with bioprosthetic valves, although limited data are available on such use. (See <a href=\"topic.htm?path=antithrombotic-therapy-for-prosthetic-heart-valves-indications#H50746474\" class=\"medical medical_review\">&quot;Antithrombotic therapy for prosthetic heart valves: Indications&quot;, section on 'DOAC may be used with a bioprosthetic valve'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical reassessment for symptoms and signs of obstruction and imaging by transthoracic echocardiography (TTE) plus either transesophageal echocardiography (TEE) or multidetector computed tomography (MDCT) to reassess valve gradient and valve appearance after at least 30 days of therapeutic anticoagulation.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If there is symptomatic obstruction and inadequate reduction in valve gradient (defined as less than 50 percent reduction in mean gradient), the adequacy of anticoagulation should be evaluated and:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If the patient is stable and the transvalvular gradient is not increasing, anticoagulation may be continued for successive 30-day intervals followed by reassessment of valve gradient and appearance.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If there are worsening symptoms of obstruction, increasing transvalvular gradient along with lack of resolution of thrombus after one or more 30-day trials of VKA, we suggest referral to a Heart Valve Team for valve surgery (see <a href=\"#H1064840080\" class=\"local\">'Referral to Heart Valve Team'</a> below). Some experts also consider a TViV procedure in this setting. In our experience, fibrinolytic therapy is unlikely to improve clinical status in patients with a bioprosthetic valve who have failed a 30-day trial of VKA. </p><p/><p class=\"bulletIndent3\">Alternatively, some experts offer fibrinolytic therapy to patients who have failed a course of anticoagulation. Scant data are available on the optimum duration of a trial of anticoagulation prior to fibrinolytic therapy.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If there is BPVT with asymptomatic obstruction or no obstruction and there is an inadequate response to anticoagulation, the adequacy of anticoagulation should be reevaluated, and the patient&rsquo;s symptoms and signs, valve appearance, and gradient should be followed closely (eg, every 30 days) as anticoagulation is continued. Some experts offer fibrinolytic therapy to patients who have failed a course of anticoagulation. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with BPVT who respond to VKA therapy, management of long-term antithrombotic therapy is discussed below. (See <a href=\"#H2926435439\" class=\"local\">'Antithrombotic therapy after an event'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H3118011101\"><span class=\"h4\">Right-sided valve thrombosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with obstructive right-sided BPVT, we suggest fibrinolytic therapy rather than anticoagulation. This recommendation is based upon limited observational evidence in patients with right-sided BPVT and indirect evidence from observational studies in patients with right-sided mechanical PVT. Options for patients with refractory right-sided BPVT are valve surgery or a TViV procedure. (See <a href=\"#H420377861\" class=\"local\">'Evidence on fibrinolytic protocols'</a> below and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1679702231\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For right-sided PVT'</a>.)</p><p>For patients with nonobstructive right-sided BPVT, the treatment is the same as for patients with nonobstructive left-sided BPVT. (See <a href=\"#H3374411767\" class=\"local\">'Left-sided valve thrombosis'</a> above.)</p><p class=\"headingAnchor\" id=\"H2299799762\"><span class=\"h3\">For other prosthetic valve findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients evaluated for BPVT <span class=\"nowrap\">and/or</span> obstruction have findings that are nondiagnostic. The following approach is suggested for such patients:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bioprosthetic cusp <span class=\"nowrap\">thickening/mass</span> strongly suggestive of thrombus with normal cusp motion and no bioprosthetic valve obstruction. If there is cusp thickening or mass strongly suggestive of thrombus, we suggest treatment as for patients with a presumptive diagnosis of thrombosis. (See <a href=\"#H2967841569\" class=\"local\">'For valve thrombosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limited bioprosthetic cusp motion with no bioprosthetic valve <span class=\"nowrap\">thickening/mass</span> and no bioprosthetic valve obstruction. Bioprosthetic valve cusp immobility alone is not diagnostic of BPVT [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/15\" class=\"abstract_t\">15</a>]. These patients should continue to take low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and undergo close (eg, within three months) monitoring with clinical and echocardiographic follow-up for development of symptoms or change in prosthetic valve appearance or gradient. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No or nonspecific bioprosthetic valve abnormalities (ie, bioprosthetic cusp thickening with normal cusp motion) with no bioprosthetic valve obstruction. Routine follow-up is recommended for these patients. (See <a href=\"topic.htm?path=overview-of-the-management-of-patients-with-prosthetic-heart-valves#H562032156\" class=\"medical medical_review\">&quot;Overview of the management of patients with prosthetic heart valves&quot;, section on 'Schedule of follow-up'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2161656995\"><span class=\"h2\">Components of therapy</span></p><p class=\"headingAnchor\" id=\"H141470734\"><span class=\"h3\">Medical therapy for heart failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients with symptomatic prosthetic valve obstruction, medical therapy for HF is used primarily as a temporizing measure for patients awaiting definitive treatment of the cause of obstruction and as palliation (eg, for patients with obstructive pannus who are not candidates for valve surgery or transcatheter valve intervention). Medical treatment of symptomatic HF may include cautious use of diuretics and other medical therapy (eg, beta blockers for heart rate control, and angiotensin converting enzyme inhibitor), given risk of destabilization with attempted therapy.</p><p>Limited data are available on the efficacy of medical management of HF in this setting, but the expected prognosis with only medical treatment of HF is poor given the known natural history of medically treated severe symptomatic valve stenosis.</p><p class=\"headingAnchor\" id=\"H1836028158\"><span class=\"h3\">Optimizing antithrombotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited evidence is available to guide management of patients with BPVT. Observational studies suggest that biologic obstructive or nonobstructive BPVT can be successfully treated with anticoagulation with a VKA (eg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>) as an alternative to surgery or fibrinolysis [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/16,22-24\" class=\"abstract_t\">16,22-24</a>] (<a href=\"image.htm?imageKey=CARD%2F109543\" class=\"graphic graphic_movie graphicRef109543 \">movie 1</a>). In a report including 15 patients with BPVT treated with VKA, symptomatic improvement was observed in all initially symptomatic patients (with only one patient developing symptoms during therapy) and time to detection of improvement in gradient ranging from 25 to 362 days [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/16\" class=\"abstract_t\">16</a>]. Three of the four patients with tricuspid BPVT improved more than 100 days after initiation of antithrombotic therapy.</p><p class=\"headingAnchor\" id=\"H1064840080\"><span class=\"h3\">Referral to Heart Valve Team</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Referral to a Heart Valve Team is recommended for a patient with bioprosthetic valve obstruction <span class=\"nowrap\">and/or</span> thrombosis with an indication for valve surgery or transcatheter valve intervention.</p><p>The Heart Valve Team performs an individualized assessment of the risk-benefit of treatment options including consideration of the following factors modified from the 2017 focused update of the 2014 <span class=\"nowrap\">AHA/ACC</span> valve guidelines [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/21\" class=\"abstract_t\">21</a>]. These factors are based largely on data in patients with left-sided mechanical valve thrombosis (see <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H2812891314\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For left-sided PVT'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The following factors favor fibrinolysis as an acute option for urgent treatment of BPVT: Presumptive diagnosis of thrombus, high surgical risk, no contraindication to fibrinolysis, first-time episode of valve thrombosis, NYHA class I to II, small clot (&le;1.0 cm<sup>2</sup> in area) or mobile thrombus &lt;0.3 cm in diameter, absence of left atrial thrombus, lack of other indications for cardiac surgery (eg, coronary artery bypass grafting [CABG] or other valve surgery), right-sided valve prosthesis, no surgical expertise available.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The following factors favor surgery: Imaging features consistent with pannus, low surgical risk, large thrombus (&gt;1.0 cm<sup>2</sup>) or mobile thrombus &ge;0.3 cm in diameter, left atrial thrombus, concomitant indication for cardiac surgery (eg, CABG or other valve surgery), contraindication to fibrinolysis, and available surgical expertise.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The following factors favor transcatheter intervention (valve-in-valve procedure): Imaging features consistent with pannus, high surgical risk, absence of valve thrombosis and absence of left atrial thrombus, no need for cardiac surgery, no evidence of endocarditis, and available interventional expertise.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with an indication for surgery or transcatheter intervention, palliative care may be appropriate if the patient&rsquo;s life expectancy is &le;1 year or the patient&rsquo;s quality of life is not expected to improve with surgical or transcatheter intervention. </p><p/><p class=\"headingAnchor\" id=\"H2362151669\"><span class=\"h3\">Fibrinolysis</span></p><p class=\"headingAnchor\" id=\"H2613538528\"><span class=\"h4\">Fibrinolytic protocol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with BPVT with an indication for fibrinolysis (also known as thrombolysis), we suggest use of the following ultraslow infusion low-dose protocol based upon observational studies largely in patients with mechanical BPVT described separately [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H250781584\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'Evidence'</a>.)</p><p>Follow-up imaging is performed to evaluate the efficacy of fibrinolytic therapy with TTE generally used to identify effect on the gradient across the prosthetic valve in cases of obstruction and TEE generally used to identify thrombus size and prosthesis appearance.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Assess for contraindications to fibrinolytic therapy (which are the same as those in the setting of myocardial infarction). (See <a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy#H1171216482\" class=\"medical medical_review\">&quot;Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy&quot;, section on 'Contraindications'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If thrombolysis is contraindicated, refer for valve surgery (thrombectomy or redo valve replacement).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If no contraindications to fibrinolysis, hold anticoagulants and wait until INR is &lt;2.5 (or activated partial thromboplastin time [aPTT] &lt;50 seconds if patient was receiving UFH).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administer IV 25 mg <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> infused over 25 hours with no bolus. This is followed by a six-hour infusion of UFH (70 <span class=\"nowrap\">unit/kg</span> bolus and 16 <span class=\"nowrap\">unit/kg/hour</span> [up to 1000 <span class=\"nowrap\">units/hour]</span> with a target aPTT of 1.5 to 2.0 times the control value). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with prosthetic valve obstruction, perform TTE to assess prosthetic valve gradient. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If gradient is reduced, perform TEE: </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If TEE shows partial resolution of thrombus (&lt;75 percent reduction in size), repeat 25 mg <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> infusion over 25 hours followed by a six-hour infusion of UFH, and then repeat TEE. </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If TEE shows complete resolution of thrombus (&ge;75 percent reduction in size), stop <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> and start UFH and VKA. (See <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1316374810\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'Antithrombotic therapy after resolution of valve thrombosis'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If gradient is not improved, repeat 25 mg <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> infusion over 25 hours followed by six-hour infusion of UFH, and then repeat TTE.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with nonobstructive thrombosis, repeat TEE. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If thrombus is completely resolved (&ge;75 percent reduction in size), stop <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> and start UFH and VKA. (See <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1316374810\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'Antithrombotic therapy after resolution of valve thrombosis'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If thrombus is unchanged or only partially resolved (&lt;75 percent reduction in size), repeat 25 mg <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> infusion over 25 hours followed by UFH six-hour infusion, then repeat TEE.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with persistent thrombus on repeat TEE, the <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> 25 mg infusion over 25 hours (followed by UFH six-hour infusion) can be repeated as needed (with TEE evaluation after each dose) up to a maximum cumulative dose of 200 mg of alteplase. Most patients are expected to require three or fewer fibrinolytic sessions [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/19,20\" class=\"abstract_t\">19,20</a>].</p><p/><p>IV UFH is held during infusion of the fibrinolytic agent. We suggest continuing <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> during infusion of fibrinolytic therapy. </p><p>Immediately after completing the fibrinolytic agent infusion, IV UFH is administered to achieve an aPTT 2.0 to 2.5 times control. Follow-up imaging is performed to evaluate the efficacy of fibrinolytic therapy with TTE generally used to identify effect on the gradient across the prosthetic valve (in cases of obstruction) and TEE generally used to identify effect on thrombus size and appearance.</p><p>When successful thrombolysis has been confirmed, VKA therapy is initiated. UFH is continued until VKA achieves the target INR for two consecutive days [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/2\" class=\"abstract_t\">2</a>]. Management of antithrombotic therapy after valve thrombosis is discussed below. (See <a href=\"#H2926435439\" class=\"local\">'Antithrombotic therapy after an event'</a> below.)</p><p class=\"headingAnchor\" id=\"H420377861\"><span class=\"h4\">Evidence on fibrinolytic protocols</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited evidence is available to guide fibrinolytic agent use in patients with BPVT. Largely indirect observational data are available on the efficacy and safety of fibrinolytic treatment regimens for BPVT, as most of the available data are for patients with mechanical PVT, as discussed in detail separately. Publications on fibrinolysis in patients with BPVT are largely limited to case reports [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/16,25-27\" class=\"abstract_t\">16,25-27</a>]. Studies using an echocardiogram-guided ultraslow infusion, low-dose fibrinolytic protocol in patients with mechanical PVT have demonstrated high rates of efficacy (85 to 90 percent or higher) with relatively low rates of complications (eg, 6.7 percent, including a 0.8 percent mortality rate, with a 25-hour infusion) [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/19\" class=\"abstract_t\">19</a>]. Complications following fibrinolytic therapy include major bleeding, systemic embolism, recurrent PVT, and death [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/28-30\" class=\"abstract_t\">28-30</a>]. Risk factors for complications in patients with mechanical PVT receiving slow (or ultraslow) infusion fibrinolytic therapy include NYHA class III or IV and large thrombus size (eg, area on TEE &ge;1 cm<sup>2 </sup>[<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/19,20\" class=\"abstract_t\">19,20</a>]). (See <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H250781584\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'Evidence'</a>.)</p><p class=\"headingAnchor\" id=\"H2776974637\"><span class=\"h3\">Transcatheter intervention</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Transcatheter valve implantation in an obstructed, surgically inserted bioprosthetic valve is the procedure of choice for patients with symptomatic severe bioprosthetic obstruction with high or greater operative risk (ie, STS operative risk score &gt;8 percent or a &gt;15 percent risk of mortality at 30 days) with valve surgery. For patients with symptomatic bioprosthetic valve obstruction who are judged by a Heart Valve Team to be at intermediate or low risk for open surgical therapy (ie, STS operative risk score &le;8 percent or a &le;15 percent risk of mortality at 30 days), we suggest surgical valve replacement or a TViV procedure at a center with expertise in this procedure. </p><p class=\"headingAnchor\" id=\"H2987427180\"><span class=\"h4\">Aortic valve-in-valve procedure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In a systematic review including 14 observational studies of aortic valve-in-valve procedures, the patient&rsquo;s mean age was 78 years, and the mean STS score was 11.3 [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/31\" class=\"abstract_t\">31</a>]. The causes of aortic bioprosthesis failure included obstruction as well as regurgitation and mixed dysfunction. The rate of successful transcatheter valve implantation was 94.7 percent, and the mean 30-day mortality rate was 8 percent. Mean rates of periprocedural complications were valve <span class=\"nowrap\">malpositioning/embolization</span> (12.4 percent), stroke (1.4 percent), pacemaker implantation (7.6 percent), and coronary obstruction (2.2 percent). The mean transvalvular gradient after aortic valve-in-valve procedure was 15.5 mmHg. The rate of severe patient prosthesis mismatch (defined as an effective orifice area &lt;0.65 cm<sup>2</sup><span class=\"nowrap\">/m<sup>2</sup>)</span> was 32.1 percent. Among the studies with one-year data, the mean mortality rate at one year was 15.1 percent (range 0 to 16.8 percent). There was a higher risk of mortality at one year (approximately 25 percent) among patients treated for bioprosthetic valve obstruction. </p><p>Data comparing TViV with surgical replacement are limited, but they suggest noninferiority with similar mortality, stroke, and survival rates [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/32\" class=\"abstract_t\">32</a>]. An observational study of 69 patients undergoing surgical aortic valve replacement (SAVR) and 22 patients undergoing TViV used STS risk scores to create 22 matched pairs of SAVR and TViV for comparison (STS scores 7.7 and 7.5) [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/32\" class=\"abstract_t\">32</a>]. Operative mortality was 4.3 in the SAVR group and zero for the TViV group. Mild paravalvular regurgitation was seen in none of the SAVR group and in 22 percent of the TViV group. Postoperative stroke rate was 9 percent for SAVR and zero for TViV. Actuarial survival at three years was 76.3 percent for SAVR and 78.7 percent for TViV. </p><p class=\"headingAnchor\" id=\"H3542144915\"><span class=\"h4\">Mitral valve-in-valve procedure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited data suggest that transcatheter mitral valve-in-valve can also be performed safely in selected patients with results comparable to those with surgical therapy. A report of the <span class=\"nowrap\">STS/ACC</span> Transcatheter Valve Therapy Registry included 349 patients who underwent mitral valve-in-valve or valve-in-ring procedures [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/33\" class=\"abstract_t\">33</a>]. The median patient age was 76 years, and median STS predicted risk of mortality for mitral valve replacement was 11 percent. The observed hospital mortality was 7.2 percent, and the 30-day mortality rate was 8.5 percent. Postoperative complications included atrial fibrillation in 4 percent, cardiac arrest in 3.4 percent, stroke in 1.1 percent, acute kidney injury requiring dialysis in 2.9 percent, life-threatening bleeding in 4.6 percent, and major vascular access complication in 0.6 percent.</p><p>A review of later (&gt;3 months) outcomes following mitral valve-in-valve or valve-in-ring procedures included seven studies with a total of 93 patients [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/31\" class=\"abstract_t\">31</a>]. The mortality rate after a mean follow-up of 14 months was 20.5 percent. Four cases of valve thrombosis were reported more than 30 days after a valve-in-valve procedure. One patient underwent a second valve-in-valve implantation due to transcatheter valve migration two months after an initially successful procedure.</p><p class=\"headingAnchor\" id=\"H835657915\"><span class=\"h3\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited data are available on treatment options for symptomatic severe bioprosthetic valve obstruction or for high-risk (mobile or large) left-sided bioprosthetic valve thrombus. Data are lacking on the natural history of these conditions. However, indirect data are available from observational studies of patients with symptomatic severe native valve disease showing high mortality risk for patients treated medically, lack of efficacy of medical therapy, and association between surgical treatment and improved symptoms and survival rates. </p><p>As an example, in patients with symptomatic severe aortic stenosis, natural history studies have shown that average survival after the onset of these symptoms is only two to three years. There is a high risk of sudden death in symptomatic patients who are followed conservatively. Although randomized trials comparing surgery with continued medical therapy have not been performed, observational studies have found that corrective surgery in this setting is followed by symptomatic improvement and a substantial increase in survival [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/2,34-40\" class=\"abstract_t\">2,34-40</a>]. (See <a href=\"topic.htm?path=indications-for-valve-replacement-in-aortic-stenosis-in-adults#H6\" class=\"medical medical_review\">&quot;Indications for valve replacement in aortic stenosis in adults&quot;, section on 'Symptomatic patients'</a>.)</p><p>Surgical management of bioprosthetic valve obstruction is limited by the high risk of the procedure, with operative mortality rates around 5 to 10 percent and survival varying from 40 to 50 percent at 10 years [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/41-45\" class=\"abstract_t\">41-45</a>]. The operative mortality following redo prosthetic valve replacement is generally higher than that for primary valve replacement (eg, 4.6 versus 2.2 percent) [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/43\" class=\"abstract_t\">43</a>]. However, some studies have found that a non-urgent redo procedure in patients with NYHA functional class <span class=\"nowrap\">I/II</span> symptoms and absence of active endocarditis has the same surgical risk as a first valve surgery [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/46\" class=\"abstract_t\">46</a>]. </p><p class=\"headingAnchor\" id=\"H2926435439\"><span class=\"h2\">Antithrombotic therapy after an event</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with BPVT treated with antithrombotic therapy <span class=\"nowrap\">and/or</span> fibrinolytic therapy are at risk for progressive or recurrent PVT [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Thus, these patients require careful follow-up including an optimized antithrombotic (anticoagulant plus antiplatelet) regimen.</p><p>When PVT occurs, a key initial step is to determine which antithrombotic agents (eg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>) the patient was taking and the adequacy of anticoagulation (including recent duration of time in the therapeutic range). The risk of bleeding complications with increased intensity of anticoagulation should also be assessed.</p><p>If antithrombotic therapy was inadequate prior to valve thrombosis or thromboembolism, institution of adequate therapy, including optimization of INR range (eg, with patient education, more frequent monitoring, management by a dedicated pharmacist-led anticoagulation clinic), should be the first therapeutic step [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>The following approach is suggested for patients with prosthetic valves who have thromboembolism or valve thrombosis despite therapeutic antithrombotic therapy, although data to guide these practices are limited:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with thromboembolism treated with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (75 to 100 mg daily) alone (eg, most patients with bioprosthetic valves), VKA may be added. VKA is generally recommended in patients with history of medically treated PVT. </p><p/><p class=\"bulletIndent1\">The appropriate duration of anticoagulant therapy after BPVT is uncertain. We continue anticoagulant therapy for at least six months after thrombus resolution in this setting. For patients who are at low risk for bleeding, we continue VKA therapy lifelong, as BPVT may recur in the absence of VKA therapy. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with thromboembolism who were adequately anticoagulated with VKA (eg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>) but not receiving <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, add aspirin (75 to 100 <span class=\"nowrap\">mg/day)</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with thromboembolism or valve thrombosis while anticoagulated to a goal INR of 2.5 and taking <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, increase the goal INR to 3.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with thromboembolism or valve thrombosis while anticoagulated to a goal INR of 3 plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, the goal INR may need to be increased to 3.5 to 4.5.</p><p/><p>The above approach is generally consistent with the 2014 <span class=\"nowrap\">AHA/ACC</span> valvular heart disease guidelines [<a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H665752789\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-cardiac-valve-disease\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Cardiac valve disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3265854583\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H4058249227\"><span class=\"h2\">Evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The evaluation of patients with suspected bioprosthetic valve thrombosis (BPVT) <span class=\"nowrap\">and/or</span> obstruction guides appropriate management (<a href=\"image.htm?imageKey=CARD%2F116059\" class=\"graphic graphic_algorithm graphicRef116059 \">algorithm 1</a>). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial evaluation of BPVT <span class=\"nowrap\">and/or</span> bioprosthetic valve obstruction includes identification of patients suspected of having either or both of these disorders and initial imaging (generally by transthoracic echocardiography [TTE]) including determination of whether prosthetic valve obstruction (or regurgitation) is present. (See <a href=\"#H642780392\" class=\"local\">'Initial evaluation'</a> above and <a href=\"topic.htm?path=clinical-manifestations-and-initial-evaluation-of-prosthetic-valve-thrombosis-and-obstruction#H3800172701\" class=\"medical medical_review\">&quot;Clinical manifestations and initial evaluation of prosthetic valve thrombosis and obstruction&quot;, section on 'Initial evaluation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Further evaluation of BPVT <span class=\"nowrap\">and/or</span> obstruction includes additional imaging of the bioprosthetic valve by transesophageal echocardiography (TEE) <span class=\"nowrap\">and/or</span> four-dimensional volume-rendered computed tomography (4D CT), exclusion of prosthetic valve endocarditis, and determining whether imaging findings are consistent with valve thrombosis. For patients with a thromboembolic event, comprehensive evaluation for alternative causes should be conducted. (See <a href=\"#H1561130580\" class=\"local\">'Further evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with bioprosthetic valve obstruction causing moderate to severe symptoms (New York Heart Association [NYHA] functional class III or IV) or high-risk left-sided valve thrombus (ie, a mobile thrombus &gt;0.3 cm in diameter or any thrombus with area &ge;1.0 cm<sup>2</sup>), urgent evaluation and management is indicated. (See <a href=\"#H3005844480\" class=\"local\">'Urgent management of bioprosthetic valve obstruction or high-risk thrombus'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1541318134\"><span class=\"h2\">Urgent therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urgent therapy for patients with bioprosthetic valve obstruction with NYHA class III to IV symptoms include medical therapy for heart failure (HF) as a temporizing measure and therapy to treat the cause of obstruction (thrombus or <span class=\"nowrap\">pannus/calcification)</span>. (See <a href=\"#H3005844480\" class=\"local\">'Urgent management of bioprosthetic valve obstruction or high-risk thrombus'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For obstructive thrombosis: </strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Left-sided:</strong> Patients with obstructive, left-sided BPVT causing NYHA class III to IV symptoms require urgent intervention. For most of these patients, we suggest surgery rather than fibrinolysis (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This recommendation is based upon indirect evidence from observational studies in patients with mechanical PVT showing low efficacy and high rates of complications in patients with moderate to severe symptoms treated with fibrinolytic therapy. (See <a href=\"#H835657915\" class=\"local\">'Surgery'</a> above and <a href=\"#H2362151669\" class=\"local\">'Fibrinolysis'</a> above and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H2287838960\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'Fibrinolytic therapy'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Right-sided:</strong> Patients with right-sided obstructive BPVT causing NYHA class III to IV symptoms require urgent intervention. For most of these patients, we suggest fibrinolysis rather than surgery. This recommendation is based upon very limited observational evidence in patients with right-sided obstructive BPVT and indirect observational studies in patients with mechanical valve PVT. (See <a href=\"#H420377861\" class=\"local\">'Evidence on fibrinolytic protocols'</a> above and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1679702231\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For right-sided PVT'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For mobile or large left-sided thrombosis: </strong>Patients with left-sided BPVT (obstructive or nonobstructive) with a mobile thrombus &ge;0.3 cm in diameter or a large nonmobile thrombus (&ge;1.0 cm<sup>2</sup>) require urgent intervention. For most of these patients, we suggest surgery rather than fibrinolysis (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This recommendation is based upon indirect evidence from observational studies in patients with left-sided mechanical valve thrombosis. (See <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H2812891314\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For left-sided PVT'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For pannus or calcification: </strong>Patients with bioprosthetic valve obstruction due to pannus or calcification causing moderate to severe symptoms (NYHA functional class III or IV) require urgent intervention; the treatment options are surgery, transcatheter intervention, or palliative care. (See <a href=\"#H835657915\" class=\"local\">'Surgery'</a> above and <a href=\"#H2776974637\" class=\"local\">'Transcatheter intervention'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For such patients who are judged by a Heart Valve Team to be at high or greater risk for open surgical therapy (ie, Society of Thoracic Surgeons [STS] operative risk score &gt;8 percent or a &gt;15 percent risk of mortality at 30 days), we suggest a transcatheter valve-in-valve (TViV) procedure at a center with expertise in this procedure (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients who are judged by a Heart Valve Team to be at low or intermediate risk with open surgical therapy (ie, STS operative risk score &le;8 percent or a &le;15 percent risk of mortality at 30 days), the options are surgical valve replacement or a TViV procedure at a center with expertise in this procedure. The available limited observational data suggest similar operative mortality, lower operative morbidity, similar long-term mortality, and higher risk of paravalvular regurgitation with TViV compared with surgical valve replacement. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For <span class=\"nowrap\">pannus/calcification</span> plus thrombus:</strong> For patients with clinical and imaging features consistent with BPVT plus pannus or calcification with moderately to severely symptomatic obstruction, the treatment options are fibrinolysis or surgery. Surgery is generally preferred in this setting because fibrinolysis has no effect on pannus and would be unlikely to result in complete resolution of the obstruction. Fibrinolysis is an option only for hemodynamically stable patients who have clear evidence of predominant thrombus. </p><p/><p class=\"headingAnchor\" id=\"H4194475061\"><span class=\"h2\">Non-urgent therapy</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For obstruction: </strong>For patients with asymptomatic or mildly symptomatic (NYHA functional class I or II) prosthetic valve obstruction, management is aimed at treating symptoms of HF and treating the obstruction (eg, thrombus or pannus). (See <a href=\"#H3506535411\" class=\"local\">'For prosthetic valve obstruction'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>For thrombosis:</strong> </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span><strong>Left-sided:</strong> For patients with obstructive left-sided BPVT, we suggest a trial of anticoagulation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We treat with one or more 30-day trials of vitamin K antagonist (VKA). <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> 75 to 100 <span class=\"nowrap\">mg/day</span> is continued. (See <a href=\"#H2967841569\" class=\"local\">'For valve thrombosis'</a> above and <a href=\"#H1836028158\" class=\"local\">'Optimizing antithrombotic therapy'</a> above.)</p><p/><p class=\"bulletIndent3\">If there are worsening symptoms of obstruction and increasing transvalvular gradient along with lack of resolution of thrombus after one or more 30-day trials of VKA (as described above), we suggest referral to a Heart Valve Team for valve surgery (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>) (see <a href=\"#H1064840080\" class=\"local\">'Referral to Heart Valve Team'</a> above). Some experts also consider a TViV procedure in this setting. In our experience, fibrinolytic therapy is unlikely to improve clinical status in patients with a bioprosthetic valve who have failed a 30-day trial of VKA. </p><p/><p class=\"bulletIndent3\">Alternatively, some experts offer fibrinolytic therapy to patients who have failed anticoagulation. </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span><strong>Right-sided:</strong> For patients with obstructive right-sided BPVT, we suggest fibrinolytic therapy rather than anticoagulation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This recommendation is based upon limited observational evidence in patients with right-sided BPVT and indirect evidence from observational studies in patients with right-sided mechanical PVT. Options for patients with refractory right-sided BPVT are valve surgery and a TViV procedure. (See <a href=\"#H420377861\" class=\"local\">'Evidence on fibrinolytic protocols'</a> above and <a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction#H1679702231\" class=\"medical medical_review\">&quot;Management of mechanical prosthetic valve thrombosis and obstruction&quot;, section on 'For right-sided PVT'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>For pannus or calcification:</strong> If a patient with mildly symptomatic obstruction has a presumptive diagnosis of pannus or calcification, the patient is referred to a Heart Valve Team for an individualized assessment of the <span class=\"nowrap\">risk/benefit</span> of valve surgery, transcatheter intervention, or palliative care. The approach to choosing between open surgery and transcatheter intervention is the same as that described above for patients with moderately to severely symptomatic obstruction. (See <a href=\"#H3506535411\" class=\"local\">'For prosthetic valve obstruction'</a> above and <a href=\"#H1064840080\" class=\"local\">'Referral to Heart Valve Team'</a> above and <a href=\"#H2776974637\" class=\"local\">'Transcatheter intervention'</a> above and <a href=\"#H835657915\" class=\"local\">'Surgery'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>For nonobstructive thrombus: </strong>For patients with nonobstructive small (nonmobile and &lt;1.0 cm<sup>2</sup> or mobile and &lt;0.3 cm in diameter) left-sided (ie, aortic or mitral) BPVT or nonobstructive right-sided BPVT (any size), we suggest anticoagulation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We treat with one or more 30-day trials of VKA; <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> 75 to 100 mg daily is continued during this therapy. (See <a href=\"#H2967841569\" class=\"local\">'For valve thrombosis'</a> above and <a href=\"#H1836028158\" class=\"local\">'Optimizing antithrombotic therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/1\" class=\"nounderline abstract_t\">Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/2\" class=\"nounderline abstract_t\">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/3\" class=\"nounderline abstract_t\">Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:2739.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/4\" class=\"nounderline abstract_t\">Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 1993; 328:1289.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/5\" class=\"nounderline abstract_t\">Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/6\" class=\"nounderline abstract_t\">D&uuml;rrleman N, Pellerin M, Bouchard D, et al. Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute. J Thorac Cardiovasc Surg 2004; 127:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/7\" class=\"nounderline abstract_t\">Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 2007; 93:137.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/8\" class=\"nounderline abstract_t\">Ozkan M, G&uuml;rsoy OM, Astarc&#305;o&#287;lu MA, et al. Real-time three-dimensional transesophageal echocardiography in the assessment of mechanical prosthetic mitral valve ring thrombosis. Am J Cardiol 2013; 112:977.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/9\" class=\"nounderline abstract_t\">Makkar RR, Fontana G, Jilaihawi H, et al. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med 2015; 373:2015.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/10\" class=\"nounderline abstract_t\">Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings. J Am Coll Cardiol 2009; 53:436.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/11\" class=\"nounderline abstract_t\">Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging 2013; 6:185.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/12\" class=\"nounderline abstract_t\">Zou H, Zhang Y, Tong J, Liu Z. Multidetector computed tomography for detecting left atrial/left atrial appendage thrombus: a meta-analysis. Intern Med J 2015; 45:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/13\" class=\"nounderline abstract_t\">Puri R, Auffret V, Rod&eacute;s-Cabau J. Bioprosthetic Valve Thrombosis. J Am Coll Cardiol 2017; 69:2193.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/14\" class=\"nounderline abstract_t\">Kagiyama N, Okura H, Nezuo S, et al. Two cases of acute bioprosthetic mitral valve thrombosis immediately after mitral valve replacement. Circulation 2014; 129:e328.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/15\" class=\"nounderline abstract_t\">Waterbury TM, Raphael CE, Padang R, et al. Not All Immobile Bioprosthetic Valve Cusps Are Thrombosed. JACC Cardiovasc Interv 2017; 10:e117.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/16\" class=\"nounderline abstract_t\">Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015; 47:725.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/17\" class=\"nounderline abstract_t\">Egbe AC, Connolly HM, Pellikka PA, et al. Outcomes of Warfarin Therapy for Bioprosthetic Valve Thrombosis of Surgically Implanted Valves: A Prospective Study. JACC Cardiovasc Interv 2017; 10:379.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/18\" class=\"nounderline abstract_t\">Biteker M, Altun I, Basaran O, et al. Treatment of Prosthetic Valve Thrombosis: Current Evidence and Future Directions. J Clin Med Res 2015; 7:932.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/19\" class=\"nounderline abstract_t\">&Ouml;zkan M, G&uuml;nd&uuml;z S, G&uuml;rsoy OM, et al. Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial. Am Heart J 2015; 170:409.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/20\" class=\"nounderline abstract_t\">G&uuml;nd&uuml;z S, &Ouml;zkan M, Yesin M, et al. Prolonged Infusions of Low-Dose Thrombolytics in Elderly Patients With Prosthetic Heart Valve Thrombosis. Clin Appl Thromb Hemost 2017; 23:241.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/21\" class=\"nounderline abstract_t\">Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/22\" class=\"nounderline abstract_t\">Butnaru A, Shaheen J, Tzivoni D, et al. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 2013; 112:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/23\" class=\"nounderline abstract_t\">Jander N, Kienzle RP, Kayser G, et al. Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 2012; 109:257.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/24\" class=\"nounderline abstract_t\">Sondergaard L, De Backer O, Kofoed KF, et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur Heart J 2017; 38:2201.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/25\" class=\"nounderline abstract_t\">Pozsonyi Z, Lengyel M. Successful thrombolysis of late, non-obstructive mitral bioprosthetic valve thrombosis: case report and review of the literature. J Heart Valve Dis 2011; 20:526.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/26\" class=\"nounderline abstract_t\">Parro A Jr, Carramona ML, Amaral CA, et al. Bioprosthetic mitral valve thrombosis. Importance of transesophageal echocardiography in the diagnosis and follow-up after treatment. Arq Bras Cardiol 2004; 82:346.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/27\" class=\"nounderline abstract_t\">Yesin M, Kal&ccedil;ik M, G&uuml;nd&uuml;z S, et al. Bioprostethic mitral valve thrombosis due to oral contraceptive drug use and management with ultra-slow thrombolytic therapy. Blood Coagul Fibrinolysis 2016; 27:220.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/28\" class=\"nounderline abstract_t\">Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. J Am Coll Cardiol 2003; 41:653.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/29\" class=\"nounderline abstract_t\">Karthikeyan G, Senguttuvan NB, Joseph J, et al. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J 2013; 34:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/30\" class=\"nounderline abstract_t\">Huang G, Schaff HV, Sundt TM, Rahimtoola SH. Treatment of obstructive thrombosed prosthetic heart valve. J Am Coll Cardiol 2013; 62:1731.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/31\" class=\"nounderline abstract_t\">Paradis JM, Del Trigo M, Puri R, Rod&eacute;s-Cabau J. Transcatheter Valve-in-Valve and Valve-in-Ring for Treating Aortic and Mitral Surgical Prosthetic Dysfunction. J Am Coll Cardiol 2015; 66:2019.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/32\" class=\"nounderline abstract_t\">Ejiofor JI, Yammine M, Harloff MT, et al. Reoperative Surgical Aortic Valve Replacement Versus Transcatheter Valve-in-Valve Replacement for Degenerated Bioprosthetic Aortic Valves. Ann Thorac Surg 2016; 102:1452.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/33\" class=\"nounderline abstract_t\">Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of The&nbsp;Society&nbsp;of&nbsp;Thoracic Surgeons/American&nbsp;College of Cardiology Transcatheter Valve Therapy&nbsp;Registry. J Am Coll Cardiol 2017; 69:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/34\" class=\"nounderline abstract_t\">Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111:3316.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/35\" class=\"nounderline abstract_t\">Smith N, McAnulty JH, Rahimtoola SH. Severe aortic stenosis with impaired left ventricular function and clinical heart failure: results of valve replacement. Circulation 1978; 58:255.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/36\" class=\"nounderline abstract_t\">Murphy ES, Lawson RM, Starr A, Rahimtoola SH. Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation 1981; 64:II184.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/37\" class=\"nounderline abstract_t\">Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation 1982; 66:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/38\" class=\"nounderline abstract_t\">Lund O. Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis. Reasons for earlier operative intervention. Circulation 1990; 82:124.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/39\" class=\"nounderline abstract_t\">Kouchoukos NT, D&aacute;vila-Rom&aacute;n VG, Spray TL, et al. Replacement of the aortic root with a pulmonary autograft in children and young adults with aortic-valve disease. N Engl J Med 1994; 330:1.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/40\" class=\"nounderline abstract_t\">Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J 1988; 9 Suppl E:57.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/41\" class=\"nounderline abstract_t\">Taramasso M, Maisano F, Denti P, et al. Surgical treatment of paravalvular leak: Long-term results in a single-center experience (up to 14 years). J Thorac Cardiovasc Surg 2015; 149:1270.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/42\" class=\"nounderline abstract_t\">Bouhout I, Mazine A, Ghoneim A, et al. Long-term results after surgical treatment of paravalvular leak in the aortic and mitral position. J Thorac Cardiovasc Surg 2016; 151:1260.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/43\" class=\"nounderline abstract_t\">Kaneko T, Vassileva CM, Englum B, et al. Contemporary Outcomes of Repeat Aortic Valve Replacement: A Benchmark for Transcatheter Valve-in-Valve Procedures. Ann Thorac Surg 2015; 100:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/44\" class=\"nounderline abstract_t\">Leontyev S, Borger MA, Davierwala P, et al. Redo aortic valve surgery: early and late outcomes. Ann Thorac Surg 2011; 91:1120.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/45\" class=\"nounderline abstract_t\">Jaussaud N, Gariboldi V, Grisoli D, et al. Risk of reoperation for mitral bioprosthesis dysfunction. J Heart Valve Dis 2012; 21:56.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnosis-and-management-of-bioprosthetic-valve-thrombosis-and-obstruction/abstract/46\" class=\"nounderline abstract_t\">Maciejewski M, Piestrzeniewicz K, Bielecka-D&#261;browa A, et al. Redo surgery risk in patients with cardiac prosthetic valve dysfunction. Arch Med Sci 2011; 7:271.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 111633 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3265854583\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H3219840367\" id=\"outline-link-H3219840367\">INTRODUCTION</a></li><li><a href=\"#H1083569417\" id=\"outline-link-H1083569417\">APPROACH TO EVALUATION</a><ul><li><a href=\"#H642780392\" id=\"outline-link-H642780392\">Initial evaluation</a></li><li><a href=\"#H1561130580\" id=\"outline-link-H1561130580\">Further evaluation</a><ul><li><a href=\"#H1989277313\" id=\"outline-link-H1989277313\">- Choice between TEE or 4D CT</a><ul><li><a href=\"#H4239874177\" id=\"outline-link-H4239874177\">Characteristics of imaging tests</a><ul><li><a href=\"#H2775584315\" id=\"outline-link-H2775584315\">- Transesophageal echocardiography</a></li><li><a href=\"#H3403465757\" id=\"outline-link-H3403465757\">- 4D Computed tomography</a></li></ul></li></ul></li><li><a href=\"#H3743821520\" id=\"outline-link-H3743821520\">- Exclude prosthetic valve endocarditis</a></li></ul></li><li><a href=\"#H3346496544\" id=\"outline-link-H3346496544\">How to diagnose prosthetic valve thrombosis</a></li><li><a href=\"#H89053030\" id=\"outline-link-H89053030\">Evidence on imaging bioprosthetic valve obstruction and thrombosis</a></li></ul></li><li><a href=\"#H953686112\" id=\"outline-link-H953686112\">MANAGEMENT</a><ul><li><a href=\"#H5869880\" id=\"outline-link-H5869880\">General considerations</a></li><li><a href=\"#H3005844480\" id=\"outline-link-H3005844480\">Urgent management of bioprosthetic valve obstruction or high-risk thrombus</a><ul><li><a href=\"#H3992733555\" id=\"outline-link-H3992733555\">- Temporizing medical care</a></li><li><a href=\"#H1476339903\" id=\"outline-link-H1476339903\">- Urgent Heart Valve Team assessment</a></li><li><a href=\"#H3873861971\" id=\"outline-link-H3873861971\">- Recommendations for urgent therapy</a></li></ul></li><li><a href=\"#H1881821939\" id=\"outline-link-H1881821939\">Non-urgent management of bioprosthetic valve obstruction or thrombosis</a><ul><li><a href=\"#H3506535411\" id=\"outline-link-H3506535411\">- For prosthetic valve obstruction</a></li><li><a href=\"#H2967841569\" id=\"outline-link-H2967841569\">- For valve thrombosis</a><ul><li><a href=\"#H3374411767\" id=\"outline-link-H3374411767\">Left-sided valve thrombosis</a></li><li><a href=\"#H3118011101\" id=\"outline-link-H3118011101\">Right-sided valve thrombosis</a></li></ul></li><li><a href=\"#H2299799762\" id=\"outline-link-H2299799762\">- For other prosthetic valve findings</a></li></ul></li><li><a href=\"#H2161656995\" id=\"outline-link-H2161656995\">Components of therapy</a><ul><li><a href=\"#H141470734\" id=\"outline-link-H141470734\">- Medical therapy for heart failure</a></li><li><a href=\"#H1836028158\" id=\"outline-link-H1836028158\">- Optimizing antithrombotic therapy</a></li><li><a href=\"#H1064840080\" id=\"outline-link-H1064840080\">- Referral to Heart Valve Team</a></li><li><a href=\"#H2362151669\" id=\"outline-link-H2362151669\">- Fibrinolysis</a><ul><li><a href=\"#H2613538528\" id=\"outline-link-H2613538528\">Fibrinolytic protocol</a></li><li><a href=\"#H420377861\" id=\"outline-link-H420377861\">Evidence on fibrinolytic protocols</a></li></ul></li><li><a href=\"#H2776974637\" id=\"outline-link-H2776974637\">- Transcatheter intervention</a><ul><li><a href=\"#H2987427180\" id=\"outline-link-H2987427180\">Aortic valve-in-valve procedure</a></li><li><a href=\"#H3542144915\" id=\"outline-link-H3542144915\">Mitral valve-in-valve procedure</a></li></ul></li><li><a href=\"#H835657915\" id=\"outline-link-H835657915\">- Surgery</a></li></ul></li><li><a href=\"#H2926435439\" id=\"outline-link-H2926435439\">Antithrombotic therapy after an event</a></li></ul></li><li><a href=\"#H665752789\" id=\"outline-link-H665752789\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H3265854583\" id=\"outline-link-H3265854583\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H4058249227\" id=\"outline-link-H4058249227\">Evaluation</a></li><li><a href=\"#H1541318134\" id=\"outline-link-H1541318134\">Urgent therapy</a></li><li><a href=\"#H4194475061\" id=\"outline-link-H4194475061\">Non-urgent therapy</a></li></ul></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/111633|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/116059\" class=\"graphic graphic_algorithm\">- Approach left-sided bioprosthetic valve obstruction/thrombosis</a></li></ul></li><li><div id=\"CARD/111633|MOV\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"MOVIES\">MOVIES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/109543\" class=\"graphic graphic_movie\">- Mitral bioprosthetic thrombosis before and after anticoagulation</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antithrombotic-therapy-for-prosthetic-heart-valves-indications\" class=\"medical medical_review\">Antithrombotic therapy for prosthetic heart valves: Indications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-initial-evaluation-of-prosthetic-valve-thrombosis-and-obstruction\" class=\"medical medical_review\">Clinical manifestations and initial evaluation of prosthetic valve thrombosis and obstruction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=echocardiographic-evaluation-of-prosthetic-heart-valves\" class=\"medical medical_review\">Echocardiographic evaluation of prosthetic heart valves</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy\" class=\"medical medical_review\">Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=indications-for-valve-replacement-in-aortic-stenosis-in-adults\" class=\"medical medical_review\">Indications for valve replacement in aortic stenosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-mechanical-prosthetic-valve-thrombosis-and-obstruction\" class=\"medical medical_review\">Management of mechanical prosthetic valve thrombosis and obstruction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-risks-of-prosthetic-valves-during-pregnancy\" class=\"medical medical_review\">Management of risks of prosthetic valves during pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-patients-with-prosthetic-heart-valves\" class=\"medical medical_review\">Overview of the management of patients with prosthetic heart valves</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-cardiac-valve-disease\" class=\"medical medical_society_guidelines\">Society guideline links: Cardiac valve disease</a></li></ul></div></div>","javascript":null}